SPR Therapeutics’ new PNS system wins FDA nod

The FDA has approved SPR Therapeutics’ (Cleveland) Sprint endura (single lead) and extensa (dual lead) peripheral nerve stimulation (PNS) systems.

The minimally invasive Sprint system is the only FDA-approved percutaneous PNS system that is indicated for up to 60 days in the back and/or extremities for both chronic and acute pain and is the industry’s only dual lead capable PNS platform, according to the company.

Get the full story on our sister site, Medical Design & Outsourcing.

The post SPR Therapeutics’ new PNS system wins FDA nod appeared first on MassDevice.

from MassDevice https://ift.tt/2MTXBEe